Skip to main
LENZ

LENZ Stock Forecast & Price Target

LENZ Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

LENZ Therapeutics is a promising bio-pharmaceutical company with strong potential in its late-stage product VIZZ. With continuously increasing revenues and a strong track record of cumulative pack sales, the company is on track for growth. With its recent expansion into international markets and a strong product profile, LENZ has the potential for even further success and market penetration. Though risks exist, the company has shown good management and financial control, making it a top pick for investors looking for growth in the biopharmaceutical sector.

Bears say

LENZ Therapeutics is facing a potential opportunity for success with their novel product, VIZZ, which has shown promising real-world efficacy and safety as compared to its competitor VUITY. However, there are concerns surrounding the commercial appeal of VIZZ due to its potential manufacturing and financial limitations. Additionally, further data and analysis is needed to fully validate the success of VIZZ in the market, which could potentially impact the company's financials and overall success.

LENZ has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LENZ Therapeutics Inc (LENZ) Forecast

Analysts have given LENZ a Buy based on their latest research and market trends.

According to 5 analysts, LENZ has a Buy consensus rating as of Sep 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LENZ Therapeutics Inc (LENZ)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.